PRTFDC1

Across TCGA pan-cancer cohorts, PRTFDC1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRTFDC1 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRTFDC1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRTFDC1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC and CCRCC are the cancer types where PRTFDC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.617	0.386	.007	8	view →
CCRCC	DFS	Quartile	II,III,IV	0.816	1.000	.013	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRTFDC1–PDAC (OS)

Open the PDAC breakdown →